Last reviewed · How we verify
IMI/REL FDC
IMI/REL is a fixed-dose combination of imipenem (a carbapenem antibiotic) and relebactam (a beta-lactamase inhibitor) that works together to overcome bacterial resistance mechanisms.
IMI/REL is a fixed-dose combination of imipenem (a carbapenem antibiotic) and relebactam (a beta-lactamase inhibitor) that works together to overcome bacterial resistance mechanisms. Used for Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible gram-negative bacteria.
At a glance
| Generic name | IMI/REL FDC |
|---|---|
| Also known as | MK-7655A |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Carbapenem/beta-lactamase inhibitor combination |
| Target | Bacterial cell wall (penicillin-binding proteins); serine beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Imipenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis. Relebactam is a non-beta-lactam beta-lactamase inhibitor that protects imipenem from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and carbapenem-hydrolyzing class A beta-lactamases. This combination restores imipenem's activity against resistant gram-negative bacteria.
Approved indications
- Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible gram-negative bacteria
Common side effects
- Nausea
- Diarrhea
- Headache
- Phlebitis at infusion site
- Seizures
Key clinical trials
- Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016) (PHASE3)
- A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020) (PHASE1)
- Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMI/REL FDC CI brief — competitive landscape report
- IMI/REL FDC updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI